CLINICAL_TRIALS
trial_result
· 2024-09-19
Clinical Trial Update: Neoadjuvant Therapy of Pembrolizumab Plus Lenvatinib in Advanced RCC [Phase 2]
Summary
Phase 2 neoadjuvant trial of pembrolizumab plus lenvatinib in advanced renal cell carcinoma has completed.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Tianjin Medical University Second Hospital | Conditions: Renal Cell Carcinoma | Phase 2 | Status: COMPLETED